Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A.

Nat Commun. 2015 Apr 30;6:7002. doi: 10.1038/ncomms8002.

PMID:
25926053
2.

Arginine deprivation by Arginine Deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.

Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, Classen CF, Kreikemeye B, Linnebacher M, Maletzk C.

Cancer Biol Ther. 2015 Mar 16:0. [Epub ahead of print]

PMID:
25774632
3.

MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression.

Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O, Farazmand A.

Genes Chromosomes Cancer. 2015 Mar;54(3):129-41. doi: 10.1002/gcc.22231.

PMID:
25620079
4.

Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.

Kuehn F, Klar E, Bliemeister A, Linnebacher M.

World J Gastroenterol. 2015 Jan 7;21(1):221-8. doi: 10.3748/wjg.v21.i1.221.

5.

Establishment and characterization of cell lines from chromosomal instable colorectal cancer.

Maletzki C, Gock M, Randow M, Klar E, Huehns M, Prall F, Linnebacher M.

World J Gastroenterol. 2015 Jan 7;21(1):164-76. doi: 10.3748/wjg.v21.i1.164.

6.

E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.

Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergün S, Germer CT, Otto C.

Neoplasia. 2014 Nov 20;16(11):972-81. doi: 10.1016/j.neo.2014.09.008. eCollection 2014 Nov.

7.

Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.

Lange F, Franz B, Maletzki C, Linnebacher M, Hühns M, Jaster R.

Biomed Res Int. 2014;2014:568693. doi: 10.1155/2014/568693. Epub 2014 Sep 17.

8.

Accounting for randomness in measurement and sampling in studying cancer cell population dynamics.

Ghavami S, Wolkenhauer O, Lahouti F, Ullah M, Linnebacher M.

IET Syst Biol. 2014 Oct;8(5):230-41. doi: 10.1049/iet-syb.2013.0031.

PMID:
25257023
9.

Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B.

Biochem Pharmacol. 2014 Nov 15;92(2):312-25. doi: 10.1016/j.bcp.2014.07.014. Epub 2014 Jul 25.

PMID:
25069049
10.

The impact of pyrvinium pamoate on colon cancer cell viability.

Wiegering A, Uthe FW, Hüttenrauch M, Mühling B, Linnebacher M, Krummenast F, Germer CT, Thalheimer A, Otto C.

Int J Colorectal Dis. 2014 Oct;29(10):1189-98. doi: 10.1007/s00384-014-1975-y. Epub 2014 Jul 26.

PMID:
25060218
11.

Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis.

Maletzki C, Klier U, Marinkovic S, Klar E, Andrä J, Linnebacher M.

Oncotarget. 2014 Jun 30;5(12):4467-79.

12.

PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?

Hühns M, Salem T, Schneider B, Krohn M, Linnebacher M, Prall F.

Oncol Rep. 2014 May;31(5):2236-44. doi: 10.3892/or.2014.3097. Epub 2014 Mar 19.

PMID:
24647592
13.

Combinations of TLR ligands: a promising approach in cancer immunotherapy.

Stier S, Maletzki C, Klier U, Linnebacher M.

Clin Dev Immunol. 2013;2013:271246. doi: 10.1155/2013/271246. Epub 2013 Nov 25.

14.

Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who?

Maletzki C, Stier S, Linnebacher M.

Oncoimmunology. 2013 Aug 1;2(8):e25419. Epub 2013 Jul 1.

15.

Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.

Mullins CS, Schneider B, Stockhammer F, Krohn M, Classen CF, Linnebacher M.

PLoS One. 2013 Aug 7;8(8):e71070. doi: 10.1371/journal.pone.0071070. eCollection 2013.

16.

Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.

Ramer R, Walther U, Borchert P, Laufer S, Linnebacher M, Hinz B.

J Lipid Res. 2013 Nov;54(11):3116-29. doi: 10.1194/jlr.M042283. Epub 2013 Aug 12.

17.

Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy.

Maletzki C, Linnebacher M, Savai R, Hobohm U.

Cancer Immunol Immunother. 2013 Aug;62(8):1283-92. doi: 10.1007/s00262-013-1455-1. Epub 2013 Jul 6.

PMID:
23832140
18.

Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.

Mullins CS, Schubert J, Schneider B, Linnebacher M, Classen CF.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1425-31. doi: 10.1007/s00432-013-1457-6. Epub 2013 Jun 8.

PMID:
23749036
19.

Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.

Maletzki C, Schmidt F, Dirks WG, Schmitt M, Linnebacher M.

Eur J Cancer. 2013 Jul;49(11):2587-95. doi: 10.1016/j.ejca.2013.02.035. Epub 2013 Apr 2.

PMID:
23561850
20.

Tumor-infiltrating B cells come into vogue.

Linnebacher M.

World J Gastroenterol. 2013 Jan 7;19(1):8-11. doi: 10.3748/wjg.v19.i1.8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk